COLO B Coloplast A/S Class B

Coloplast A/S - Transactions in connection with share buy-back programme, week 14

Coloplast A/S - Transactions in connection with share buy-back programme, week 14

As mentioned in Announcement no. 02/2020 Coloplast is initiating a share buyback programme totalling up to DKK 500 million.

The programme will commence on 24 February 2020 and is expected to end by 24 August 2020.

The share buyback programme is carried out in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations with the purpose of meeting obligations arising from share options programmes or other allocation of shares to employees or to complete a share capital decrease as set out in Articles 5(2)(a) and 5(2)(c) in MAR.

The following transactions have been executed during the period 30 March – 3 April 2020:

DateNumber of sharesAverage purchase price, DKKTransaction value, DKK
30 March 2020500936.03468,015
31 March 20201,100974.611,072,071
01 April 2020500992.89496,445
02 April 20206,846984.186,737,696
03 April 20205001021.32510,660
Accumulated until now under the programme204,026906.16184,879,456

Henceforth, Coloplast owns 3,296,386 treasury B shares of DKK 1 equal to 1.53 % of the company’s total share capital.

An overview showing the transaction data for the period 30 March – 3 April 2020 is enclosed.

Kind regards,

Investor Relations

Coloplast A/S

Tel.

 

For further information, please contact

  

Investors and analysts

Ellen Bjurgert

Vice President, Investor Relations

Tel. /

Email:

Rasmus Sørensen

Sr. Manager, Investor Relations

Tel. /

Email:

                                                                                       

Press and the media

Lina Danstrup

Sr. Media Relations Manager

Tel. 4911 2607

Email:

Address

Coloplast A/S

Holtedam 1

DK-3050 Humlebaek

Danmark

CVR NR. 69749917

Website

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare. Our business includes Ostomy Care, Continence Care, Wound and Skin Care and Interventional Urology. We operate globally and employ about 12,000 employees.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2020-04.

All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.

Attachments

EN
06/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

 PRESS RELEASE

Coloplast A/S - Finanskalender 2025-26

Coloplast A/S - Finanskalender 2025-26 Venligst se vedlagte pdf. For yderligere information og kalenderinvitationer til kommende begivenheder, besøg venligst:  Med venlig hilsen,Investor RelationsColoplast A/STel. 4911 1800   For yderligere information, kontakt venligst Investorer og analytikereAnders Lonning-SkovgaardKoncerndirektør, CFOTlf. 4911 1111 Kristine Husted MunkSenior Director, Investor RelationsTlf. 4911 1800 / 4911 3266E-mail: Simone Dyrby HelvindSenior Manager, Investor RelationsTlf. 4911 1800 / 4911 2981E-mail: Presse og medierPeter MønsterSr. Media Relations Manage...

 PRESS RELEASE

Coloplast A/S - Financial Calendar 2025-26

Coloplast A/S - Financial Calendar 2025-26 Please see enclosed pdf. For more information and calendar invitations for upcoming events, please visit:  Kind regards,Investor RelationsColoplast A/STel.   For further information, please contact Investors and analystsAnders Lonning-SkovgaardExecutive Vice President, CFOTel. Kristine Husted MunkSenior Director, Investor RelationsTel. / Email: Simone Dyrby HelvindSenior Manager, Investor RelationsTel. / Email: Press and mediaPeter MønsterSr. Media Relations ManagerTel. Email: AddressColoplast A/SHoltedam 1DK-3050 HumlebaekDenm...

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
 PRESS RELEASE

Coloplast A/S - Coloplast lancerer ny 5-årig strategi ’Impact4’

Coloplast A/S - Coloplast lancerer ny 5-årig strategi ’Impact4’ Den nye 5-årige strategi, Impact4, vil blive lanceret i dag på selskabets Capital Markets Day 2025. Strategien Impact4 sætter kunden i centrum og udstikker samtidig et ambitiøst mål for selskabet – at hjælpe 4 millioner mennesker på lang sigt. Med Impact4 fokuserer vi på fire strategiske prioriteter, der er afgørende for vores succes og værdiskabelse: ’Grow through innovative customer offerings’ ved at sætte standarden for sundhedspleje og ved at skabe et stærkt fokus på kunderne på tværs af alle vores forretningsområder.’Unl...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch